Dendritic cell vaccines are also under investigation in pancreatic cancer clinical trials, highlighting carcinoembryonic antigen (CEA)-loaded DCs [123], mutated p53 and K-Ras loaded DCs [124], MUC1 [125], and WT-1 pulsed DCS [126]. Here, TP53 is linked to pancreatic neoplasm.